Cargando…
The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism
INTRODUCTION: Inborn errors of metabolism (IEMs) often result from single-gene mutations and collectively cause liver dysfunction in neonates leading to chronic liver and systemic disease. Current treatments for many IEMs are limited to maintenance therapies that may still require orthotropic liver...
Autores principales: | Thompson, Whitney S., Mondal, Gourish, Vanlith, Caitlin J., Kaiser, Robert A., Lillegard, Joseph B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676758/ https://www.ncbi.nlm.nih.gov/pubmed/33224636 http://dx.doi.org/10.1080/21678707.2020.1791082 |
Ejemplares similares
-
In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions
por: Nicolas, Clara T., et al.
Publicado: (2022) -
Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1
por: Hickey, Raymond D., et al.
Publicado: (2018) -
Syndrome of hereditary tyrosinemia in mink
por: Christensen, K, et al.
Publicado: (1978) -
Future of Therapy for Inborn Errors of Immunity
por: Perez, Elena
Publicado: (2022) -
GARROD'S INBORN ERRORS OF METABOLISM
Publicado: (1963)